Related Experiment Videos
Celecoxib, a COX-2--specific inhibitor: the clinical data
1Medical Affairs, G.D. Searle & Co, Skokie, Illinois, USA.
American Journal of Orthopedics (Belle Mead, N.J.)
|April 8, 1999
Summary
Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, effectively reduces pain and inflammation. It demonstrates a favorable safety profile, with fewer gastrointestinal issues and no impact on platelet function compared to traditional NSAIDs.
Area of Science:
- Pharmacology
- Inflammation and Pain Management
Background:
- Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal, renal, and platelet-related adverse effects.
- Prostaglandins mediate pain and inflammation, but also play roles in homeostasis.
Purpose of the Study:
- To evaluate the efficacy and safety of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor.
- To compare celecoxib's effects with conventional NSAIDs and placebo regarding pain, inflammation, and adverse events.
Main Methods:
- Double-blind clinical trials were conducted.
- Comparative studies assessed efficacy in osteoarthritis, rheumatoid arthritis, and post-dental extraction pain.
- Controlled trials evaluated gastroduodenal ulcer incidence and platelet function.
Main Results:
- Celecoxib demonstrated efficacy comparable to naproxen for arthritis and aspirin for pain relief.
- Significantly lower rates of gastroduodenal ulcers and erosions were observed with celecoxib compared to naproxen.
- Celecoxib did not affect platelet function, unlike aspirin.
Conclusions:
- Celecoxib is a safe and effective therapeutic option for managing arthritis and pain.
- Its selective COX-2 inhibition offers a distinct advantage over conventional NSAIDs by minimizing gastrointestinal and platelet-related side effects.